Therapy Insight: cardiovascular disease in pediatric systemic lupus erythematosus
Christy Sandborg*, Stacy P Ardoin and Laura Schanberg
Correspondence *Division of Pediatric Rheumatology, Stanford University School of Medicine, 300 Pasteur Drive, Room A085, Stanford, CA 94305, USA
Email sandborg@stanford.edu
Early-onset systemic lupus erythematosus (SLE) is thought to be associated with an increased risk to cardiovascular health as well as a severe disease phenotype. As outlined in this article, inflammatory and immune abnormalities that are intrinsic to SLE, primary dyslipidemias and secondary effects of treatments such as corticosteroids, might all contribute to premature atherosclerosis.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patientsKidney International Original Article
See all 8 matches for Research